Tens of millions of people across the U.S.
have received a coronavirus vaccine. So far, the majority of doses have been either the Moderna or
Pfizer vaccine, both of which use mRNA to
generate an immune response. These gene-based vaccines have been in the works
for decades, but this is the first time they have been used widely in people...
MRNA vaccines are proving to be more effective than anyone had hoped, but as with
any new medical advancement, people have a lot of questions. How do they work?
Are they safe? Do I really need two shots? Why do they need to be kept so cold?
And will this be the vaccine technology of the future? Below, we highlight five
articles from The Conversation that will help answer your questions about mRNA
vaccines.
1. A vaccine revolution
“DNA and mRNA
vaccines offer huge advantages over traditional types of vaccines,
since they use only genetic code from a pathogen – rather than the entire virus
or bacteria,” writes Deborah Fuller, a microbiologist at the
University of Washington who has been working on gene-based vaccines for
decades.
The Moderna and Pfizer
vaccines are proof that mRNA vaccines are ready for prime time – and far
surpass their predecessors. “The hopes that gene-based vaccines could one day
provide a vaccine for malaria or HIV, cure cancer, replace less effective
traditional vaccines or be ready to stop the next pandemic before it gets started
are no longer far-fetched,” explains Fuller.
2. How does an mRNA
vaccine work
These vaccines are not only effective, they work in a
fundamentally different way from traditional vaccines, explains Sanjay Mishra, a staff scientist at the
Vanderbilt University Medical Center.
Traditional vaccines use an entire dead virus – or just a piece of
one – to generate immunity. “But an mRNA vaccine is different,” writes Mishra,
“because rather than having the viral protein injected, a person receives
genetic material – mRNA – that encodes the viral protein. When these genetic
instructions are injected into the upper arm, the muscle cells translate them
to make the viral protein directly in the body.”
3. Quick to market, but still safe
“Safety is the first and foremost goal for a vaccine,” says William Petri, a Professor of Medicine at the
University of Virginia. A lot of people have expressed safety concerns based on
how fast these vaccines were developed, approved and distributed.
According to Petri, the vaccines still went through every normal step – they just did them simultaneously. “In my opinion, safety is not compromised by the speed of vaccine.”
4. Why is it important to get your second shot
You got your first vaccine shot. But with shortages and supply problems, getting the second dose might be becoming a hassle. Does it really matter? Yes, explains William Petri in another article.
“The first dose primes the immune system and introduces the body
to the germ of interest. This allows the immune system to prepare its defense.
The second dose, or booster, provides the opportunity for the immune system to
ramp up the quality and quantity of the antibodies used to fight the virus.”
Immunity is a complex process, and “if the booster isn’t given
within the appropriate window, lower quantities of antibodies will be produced
that may not provide as powerful protection from the virus,”
writes Petri. So go get your second shot if you can, even if you have to get it
a bit later than expected.
5. Subzero storage makes distribution a challenge
For all of their amazing attributes, mRNA vaccines do have at
least one weakness: “If they get too warm or too cold they spoil. And, just
like fish, a spoiled vaccine must be thrown away,” explains Anna Nagurney, Professor of Operations Management
at the University of Massachusetts, Amherst, who studies medical supply chains.
The mRNA molecule is very fragile, so vaccines need to be kept at
extremely cold, very specific temperatures – a challenge for distribution. “The
answer is something called the vaccine cold chain – a supply chain that
can keep vaccines in tightly controlled temperatures from the moment they are
made to the moment that they are administered to a person,” explains Nagurney.
This cold supply chain is critical to getting vaccines where they need to go,
and without it, no matter how good the vaccines are, they can’t make much of a
difference.
Daniel Merino (The
Conversation)
Assistant
Editor: Science, Health, Environment; Co-Host: The Conversation Weekly Podcast
John
F. Smith Memorial Professor of Operations Management, University of
Massachusetts Amherst
Professor
of Microbiology, School of Medicine, University of Washington
Project
Coordinator & Staff Scientist, Vanderbilt University Medical Center,
Vanderbilt University
Professor
of Medicine, University of Virginia
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.